Trametinib Dimethyl Sulfoxide
FDA-approved product (tablet, oral), marketed as Mekinist, Trametinib Dimethyl Sulfoxide.
- Registered studies
- 16
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cancer
- Cutaneous melanoma
- Glioblastoma multiforme
- Glioma
- Lung cancer
- Melanoma
- Metastatic melanoma
- Neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Mitogen-activated protein kinase (mek) inhibitors
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA60.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli57.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae44.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis57.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
16registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Trametinib Dimethyl Sulfoxide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UbrogepantExisting use: Migraine disorder53.8% AI-predicted activityagainst E. coli24 registered studies
- Caspofungin AcetateExisting use: Aspergillosis, Candidemia, Candidiasis and 1 more53.7% AI-predicted activityagainst E. coli50+ registered studies
- OdevixibatExisting use: Intrahepatic cholestasis53.7% AI-predicted activityagainst E. coli13 registered studies
- PosaconazoleExisting use: Aspergillosis, Candidiasis, Coccidioidomycosis and 2 more53.6% AI-predicted activityagainst E. coli50+ registered studies
- SiponimodExisting use: Multiple sclerosis53.6% AI-predicted activityagainst E. coli33 registered studies
- LonafarnibExisting use: Hutchinson-Gilford progeria syndrome, Laminopathies, Progeria53.6% AI-predicted activityagainst E. coli39 registered studies
- Brilliant Blue GExisting use: Disclosing Agent53.4% AI-predicted activityagainst E. coli10 registered studies
- AbarelixExisting use: Neoplasm53.4% AI-predicted activityagainst E. coli5 registered studies
- CyclosporineExisting use: Conjunctivitis, Corneal disease, Eye disease and 6 more53.3% AI-predicted activityagainst E. coli50+ registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection53.2% AI-predicted activityagainst E. coliNo documented evidence found
- Ergotamine TartrateExisting use: Headache, Migraine disorder53.1% AI-predicted activityagainst E. coli10 registered studies
- Maralixibat ChlorideExisting use: Alagille syndrome, Pruritus53.1% AI-predicted activityagainst E. coli5 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
NCT01336634 · start 2011-08-05
Registered record
- Registry ID
- NCT01336634
- Conditions
- Cancer
- Interventions
- Dabrafenib; Trametinib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2011-08-05
- Completion
- 2021-01-07
- Enrolment
- 177
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCancerInterventionDabrafenib; TrametinibPhasePhase 2Registry statusCompleted